Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

UBS Reaffirms Their Sell Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Tipranks - Tipranks - Wed Feb 25, 3:32AM CST

In a report released today, Graham Doyle from UBS maintained a Sell rating on Fresenius Medical Care AG & Co. KGaA, with a price target of €38.00.

Claim 50% Off TipRanks Premium

According to TipRanks, Doyle is an analyst with an average return of -1.4% and a 50.97% success rate. Doyle covers the Healthcare sector, focusing on stocks such as Fresenius Medical Care AG & Co. KGaA, ConvaTec, and Koninklijke Philips N.V..

In addition to UBS, Fresenius Medical Care AG & Co. KGaA also received a Sell from Jefferies’s James Vane in a report issued today. However, on the same day, Barclays maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA (LSE: 0H9X).

See today’s best-performing stocks on TipRanks >>

0H9X market cap is currently €11.74B and has a P/E ratio of 16.47.

Read More on GB:0H9X:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).